Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport

Molecular Pharmacology

Volumn 65, Issue 5, 2004, Pages 1208-1216

  Zhang, Shuzhong ^a   Yang, Xinning ^a   Morris, Marilyn E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIGENIN; AURANTIIN; BIOCHANIN A; BREAST CANCER RESISTANCE PROTEIN; CHRYSIN; DAIDZEIN; ESTRADIOL; FISETIN; FLAVANOID; FLAVONOID GLYCOSIDE; GENISTEIN; HESPERETIN; KAEMPFEROL; LUTEOLIN; MITOXANTRONE; MORIN; MYRICETIN; NARINGENIN; PHLORETIN; PHLORIZIN; QUERCETIN; SILIBININ; SILYMARIN;

ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN TRANSPORT; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CELL DIVISION; CHEMOKINES, CC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLAVONOIDS; HUMANS; MITOXANTRONE; NEOPLASM PROTEINS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 2142711101     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.65.5.1208     Document Type: Article

References (40)

1. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, and Dean M (1998) A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58:5337-5339.
2. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, and Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Wash DC) 258: 1650-1654.
3. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, and Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54:5902-5910.
4. Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, Barron D, and Di Pietro A (1998) Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 95:9831-9836.
5. Cooray HC, Blackmore CG, Maskell L, and Barrand MA (2002) Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13:2059-2063.
6. Diah SK, Smitherman PK, Aldridge J, Volk EL, Schneider E, Townsend AJ, and Morrow CS (2001) Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Cancer Res 61:5461-5467.
7. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670.
8. Eisenberg DM, Kessler RC, Van Rompay MI, Kaptchuk TJ, Wilkey SA, Appel S, and Davis RB (2001) Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 135:344-351.
9. Fairchild CR, Moscow JA, O'Brien EE, and Cowan KH (1990) Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-π. Mol Pharmacol 37:801-809.
10. Havsteen BH (2002) The biochemistry and medical significance of the flavonoids. Pharmacol Ther 96:67-202.
11. Hertog MG, Feskens EJ, Hollman PC, Katan MB, and Kromhout D (1993) Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342:1007-1011.
12. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, et al. (2002) The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 99:15649-15654.
13. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, and Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
14. Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
15. Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M, and Takebayashi Y (2001) Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 92:452-458.
16. Kohno H, Tanaka T, Kawabata K, Hirose Y, Sugie S, Tsuda H, and Mori H (2002) Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. Int J Cancer 101: 461-468.
17. Kuhnau J (1976) The flavonoids. A class of semi-essential food components: their role in human nutrition. World Rev Nutr Diet 24:117-191.
18. Leslie EM, Mao Q, Oleschuk CJ, Deeley RG, and Cole SP (2001) Modulation of multidrug resistance protein l (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids. Mol Pharmacol 59:1171-1180.
19. Litman T, Druley TE, Stein WD, and Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931-959.
20. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
21. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, and Schellens JH (1999) Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59:4559-4563.
22. Minderman H, Suvannasankha A, O'Loughlin KL, Scheffer GL, Scheper RJ, Robey RW, and Baer MR (2002) Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry 48:59-65.
23. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, et al. (1999) Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59:8-13.
24. Ni H, Simile C, and Hardy AM (2002) Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey. Med Care 40:353-358.
25. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, and Erdman JW Jr (1998) Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 68:1375S-1379S.
26. Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T, and Greenberger LM (1998) Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 68:5850-5858.
27. Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T, and Bates SE (2001a) A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 1512:171-182.
28. Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, and Bates SE (2001b) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7:145-152.
29. Ross DD, Karp JE, Chen TT, and Doyle LA (2000) Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 96:365-368.
30. Schurr E, Raymond M, Bell JC, and Gros P (1989) Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse mdr1 cDNA. Cancer Res 49:2729-2733.
31. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, et al. (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16:2986-2999.
32. Siegenthaler P, Kaye SB, Monfardini S, and Renard J (1992) Phase II trial with flavone acetic acid (NSC. 347512, LM975) in patients with non-small cell lung cancer. Ann Oncol 3:169-170.
33. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112.
34. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, and Sauerbrey A (2002) BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16:1443-1447.
35. Sugimoto Y, Tsukahara S, Imai Y, Ueda K, and Tsuruo T (2003) Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther 2:105-112.
36. Taipalensuu J, Tornblom H, Lindberg G, Einarsson C, Sjoqvist F, Melhus H, Garberg P, Sjostrom B, Lundgren B, and Artursson P (2001) Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299:164-170.
37. van der Kolk DM, Vellenga E, Scheffer GL, Muller M, Bates SE, Scheper RJ, and de Vries EG (2002) Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 99:3763-3770.
38. Volk EL, Farley KM, Wu Y, Li F, Robey RW, and Schneider E (2002) Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 62:5035-5040.
39. Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, and Baba M (2003) Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol 63:65-72.
40. Zhang S and Morris ME (2003) Effects of the flavonoids biochanin A, morin, phloretin and silymarin on P-glycoprotein-mediated transport. J Exp Pharmacol Ther 304:1258-1267.